Table 5 Recurrence rate and median recurrence-free survival (RFS) for Keyhole Limpet Hemocyanin (KLH) and mitomycin C (MM) in patients with recurrence and complete treatment course who received additional treatment after transurethral resection of bladder tumor (TURBT) for prior tumor (KLH second-line treatment)

From: Quality of transurethral resection of bladder tumor procedure influenced a phase III trial comparing the effect of KLH and mitomycin C